Skip to content
    Guidelines & Consensus

    Artificial intelligence in oncology: linking biological discovery to clinical utility

    Kuchana et alMolecular Cancer

    Artificial intelligence (AI) across the oncology continuum exhibits an evidence gradient rather than uniform clinical and biological translation, according to a systematic evidence synthesis of 202 publications encompassing 182 original studies. Although computational systems have proliferated across screening, histopathology, molecular profiling, treatment selection, and toxicity surveillance, their translational maturity varies widely by subdiscipline.
    In cancer detection and imaging, select algorithmic tools for mammography and colonoscopy are supported by randomized controlled trials confirming improved workflow efficiency and lesion detection gains. Nevertheless, negative pragmatic trials emphasize that superior technical accuracy does not inherently result in improved real-world diagnostic pathways. In computational pathology, large vision-language and self-supervised foundation models demonstrate robust cross-institutional and cross-task generalizability, but prospective real-world implementation remains rare, accompanied by inconsistent reporting of data provenance, algorithmic calibration, and subgroup performance.
    In molecular and systems oncology, graph-based, spatial transcriptomic, single-cell, and multi-omic models yield falsifiable hypotheses surrounding tumor microenvironments, gene regulation, and therapeutic vulnerabilities, yet most lack upstream functional biological validation. Furthermore, therapeutic decision-support tools—including surgical assistance platforms, toxicity monitoring systems, and clinical large language models—face persistent limitations from temporal drift, cohort heterogeneity, unstandardized endpoints, and an absence of prospective data demonstrating that model-guided intervention improves clinical outcomes. Integrating oncology AI reliably into clinical care requires a claim-matched framework utilizing external validation for transportability, randomized trials for patient survival or outcome advantages, prospective workflow analyses for operational impact, and perturbation experiments for biological mechanism.

    Key Takeaways

    • Select mammography and colonoscopy artificial intelligence tools demonstrate workflow efficiency and lesion detection gains in randomized controlled trials, although negative pragmatic trials show that high technical accuracy does not consistently translate to improved diagnostic pathways.
    • Foundational self-supervised and vision-language pathology models achieve cross-task and cross-institutional transferability, but prospective real-world clinical deployment remains scarce and exhibits inconsistent reporting of calibration and subgroup performance.
    • Therapeutic decision support tools, including clinical large language models and toxicity surveillance systems, currently lack evidence showing that model-guided care alters patient outcomes due to cohort heterogeneity, temporal drift, and unstandardized endpoints.
    Read the original sourceMolecular Cancer